Pralatrexate
- Generic Name
- Pralatrexate
- Brand Names
- Folotyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N7O5
- CAS Number
- 146464-95-1
- Unique Ingredient Identifier
- A8Q8I19Q20
- Background
Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma . Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have a hi...
- Indication
Pralatrexate is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma.
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL), Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
- Associated Therapies
- -
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Acrotech Biopharma Inc.
- Registration Number
- NCT01820091
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Acrotech Biopharma Inc.
- Registration Number
- NCT01789723
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
- Conditions
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01626664
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇫🇷Hospital Necker, Paris, France
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT01532011
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 271
- Registration Number
- NCT01482962
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
- Conditions
- Interventions
- Drug: prednisoneDrug: cyclophosphamideDrug: etoposideDrug: VincristineDrug: pralatrexateOther: laboratory biomarker analysisGenetic: comparative genomic hybridizationGenetic: gene expression analysisGenetic: nucleic acid sequencingGenetic: mutation analysisOther: immunohistochemistry staining methodGenetic: microarray analysisGenetic: RNA analysis
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 34
- Registration Number
- NCT01336933
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 29
- Registration Number
- NCT01206465
- Locations
- 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01188876
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
- Conditions
- Stage IIIB Esophageal AdenocarcinomaStage IIIC Esophageal Squamous Cell CarcinomaStage IIIC Gastric CancerStage IV Esophageal AdenocarcinomaStage IV Esophageal Squamous Cell CarcinomaUndifferentiated Gastric CarcinomaAdenocarcinoma of the Gastroesophageal JunctionEsophageal Undifferentiated CarcinomaGastric AdenocarcinomaRecurrent Esophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT01178944
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Rochester General Hospital, Rochester, New York, United States
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2016-06-01
- Target Recruit Count
- 6
- Registration Number
- NCT01129206
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.